The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs e…

Fuchs Endothelial Corneal DystrophyFuchs

~Estimated

~$10 – $8,750

Design Therapeutics, Inc.NCT07024693

Phase 2

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patien…

Fuchs Endothelial Corneal Dystrophy

~Estimated

~$10 – $7,500

Massachusetts Eye and Ear InfirmaryNCT04440280